Journal article
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Abstract
BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy.
METHODS: In this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate (1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The …
Authors
Ryan CJ; Smith MR; de Bono JS; Molina A; Logothetis CJ; de Souza P; Fizazi K; Mainwaring P; Piulats JM; Ng S
Journal
New England Journal of Medicine, Vol. 368, No. 2, pp. 138–148
Publisher
Massachusetts Medical Society
Publication Date
January 10, 2013
DOI
10.1056/nejmoa1209096
ISSN
0028-4793